TL;DR
- Karleigh McClain overdosed on a GLP-1 weight loss drug from a telehealth provider.
- Many telehealth companies are prescribing GLP-1s without adequate patient evaluation.
- The rise in online prescriptions has led to increased overdose reports.
- Critics warn about the lack of follow-up care in telehealth.
- Patients are often unaware of the risks associated with GLP-1 medications.
In the age of online convenience, the quest for weight loss has taken a perilous turn. Enter the GLP-1 weight loss drugs, which have become the latest trend for those looking to shed pounds quickly. But while these medications promise results, the safety of acquiring them through telehealth services is raising eyebrows—and for good reason.
Take the case of Karleigh McClain, a 31-year-old compliance consultant from Hendersonville, Tennessee. After just 24 hours of injecting her first dose of a GLP-1 medication prescribed by a telehealth doctor, she found herself in the hospital, battling severe side effects. “I can’t keep anything down,” she recalled, a harrowing experience that led to the realization that her prescribed dosage was nearly nine times the recommended amount for a first-time user.
As the popularity of telehealth skyrocketed during the pandemic, so did the ease of obtaining prescriptions for GLP-1s. While many patients traditionally received these medications through in-person consultations, the online world has made it alarmingly simple to get a prescription with minimal oversight. Critics argue that this convenience comes with a hidden price—safety.
Research shows that adverse experiences tied to telehealth companies are on the rise, with medication errors skyrocketing from just over 2,000 reports in 2020 to over 25,000 in 2025. Many telehealth companies are quick to prescribe these drugs without adequate patient evaluations, leading to dangerous situations for those who may not be suited for such treatments.
Elizabeth Krupinski, an experimental psychologist at Emory University, voiced her concerns, stating, “It gives a black eye to telemedicine.” She emphasized that while telehealth can benefit many, it must be integrated with in-person care to ensure patient safety. Unfortunately, that’s not always the case, as some companies prioritize profit over patient well-being.
Moreover, the lack of proper follow-up care can leave patients vulnerable. Many telehealth companies market GLP-1s as a quick fix for weight loss, often neglecting to stress the importance of a balanced diet and exercise. This approach can exacerbate existing eating disorders or even lead to new ones, as highlighted by physician Amanda Banks in her recent research.
As the demand for weight loss solutions continues to rise, the regulatory landscape for telehealth remains murky. With states loosening restrictions on telehealth practices, the potential for mismanagement is higher than ever. Some companies require virtual consultations, while others allow patients to fill out a questionnaire without ever speaking to a healthcare provider. This inconsistency raises questions about the quality of care patients receive.
In a world where convenience often trumps caution, it’s crucial for patients to be informed about the risks associated with GLP-1 medications. From overdoses to severe side effects, the dangers are real. As Leslie Gammon, another patient who experienced adverse effects, discovered, the repercussions can lead to hefty medical bills and ongoing health issues.
As telehealth continues to evolve, the need for stricter regulations and better patient education becomes increasingly urgent. Patients must be vigilant, ensuring they understand the source of their medications and the potential risks involved. The rise of GLP-1 weight loss drugs may offer a quick solution, but the safety concerns surrounding their online availability cannot be ignored.